Skip Nav Destination
Close Modal
Update search
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Article Type
Date
Availability
1-6 of 6
Keywords: glucagon-like peptide-1
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Articles
Daniel F. Arruda-Junior, Flavia L. Martins, Thiago Almeida Salles, Leonardo Jensen, Rafael Dariolli, Ednei L. Antonio, Leonardo dos Santos, Renato O. Crajoinas, Paulo J.F. Tucci, Luís Henrique W. Gowdak, José Eduardo Krieger, Alexandre C. Pereira, Adriana C. Girardi
Journal:
Clinical Science
Clin Sci (Lond) (2020) 134 (9): 1081–1094.
Published: 07 May 2020
... disturbances in glucose homeostasis and heart failure (HF) progression is bidirectional. However, the mechanisms by which HF intrinsically impairs glucose homeostasis remain unknown. The present study tested the hypothesis that the bioavailability of intact glucagon-like peptide-1 (GLP-1) is affected in HF...
Includes: Supplementary data
Articles
Journal:
Clinical Science
Clin Sci (Lond) (2018) 132 (15): 1699–1709.
Published: 16 August 2018
... for preventing microvascular complications, but the extent to which it can reduce CV complications is less certain. Glucagon-like peptide-1 (GLP-1) agonists are potent glucose-lowering agents but also have potentially beneficial effects on other traditional (body weight, blood pressure (BP), and LDL cholesterol...
Articles
Journal:
Clinical Science
Clin Sci (Lond) (2015) 129 (5): 405–414.
Published: 11 June 2015
.... In addition, it was recently reported that short-term exposure to GCs reduced the insulinotropic effects of the incretin GLP-1 (glucagon-like peptide 1). However, although defective GLP-1 secretion has been correlated with insulin resistance, potential direct effects of GCs on GLP-1-producing L-cell function...
Includes: Supplementary data
Articles
Journal:
Clinical Science
Clin Sci (Lond) (1999) 96 (4): 335–342.
Published: 01 April 1999
...-dependent insulinotropic polypeptide or glucagon-like peptide-1 (GLP-1). These findings therefore provide no support for the hypothesis that overactivity of the entero-insular axis contributes to the hyperinsulinaemia seen in obesity. Indeed, the plasma GLP-1 response to carbohydrate was markedly attenuated...
Articles
Journal:
Clinical Science
Clin Sci (Lond) (1998) 95 (6): 719–724.
Published: 01 December 1998
...C. Mark B. EDWARDS; Jeannie F. TODD; Mohammad A. GHATEI; Stephen R. BLOOM 1. Glucagon-like peptide-1 (7-36) amide (GLP-1) is a gut hormone released postprandially that stimulates insulin secretion, suppresses glucagon secretion and delays gastric emptying. The insulinotropic action of GLP-1 is more...
Articles
Journal:
Clinical Science
Clin Sci (Lond) (1997) 93 (4): 343–347.
Published: 01 October 1997
...Rousseau Gama; Fiona Norris; Linda Morgan; Shelagh Hampton; John Wright; Vincent Marks 1. We investigated whether abnormalities of gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (7–36 amide) (GLP-1) contribute to the hypertriglyceridaemia and hyperinsulinaemia...